Merck Dec 22, 2022 Merck Pays $175M Upfront for Rights to Seven Kelun-Biotech Antibody-Drug Conjugate Candidates Dec 22, 2022 Gilead Sciences, Arcus Biosciences Tout Domvanalimab NSCLC Data as Good News for Anti-TIGIT Approach Premium Dec 20, 2022 Moderna's Oncology Aspirations Grow With mRNA Vaccine Success in Melanoma Premium Dec 1, 2022 Nectin Therapeutics Enters Clinical Stage With Drug for Non-Responders to Checkpoint Inhibitors Premium Nov 17, 2022 Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear Premium Nov 8, 2022 NICE Recommends Keytruda for Neoadjuvant, Adjuvant Treatment of Triple-Negative Breast Cancer Oct 27, 2022 Keytruda Revenue Climbs 20 Percent in Q3 as Merck Continues Push Into Earlier-Stage Cancer Settings Premium Oct 14, 2022 Nucleai Hopes to Engage Pharma on Next-Gen Immunotherapies With Proof-of-Concept AI-Based Biomarker Premium Oct 12, 2022 Merck Exercises Option on Moderna Cancer Vaccine Oct 4, 2022 Personalis, Duke University, Olink Collaborate on Immunotherapy Markers in Gastric Cancer Sep 30, 2022 In Brief This Week: Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Sep 19, 2022 CancerRNA Consortium Will Harness RNA Technology to Enhance Immunotherapies Sep 13, 2022 Imaging Agent May Have Potential as Noninvasive Test to Predict PARP Inhibitor Response Sep 6, 2022 UK's MHRA Approves Adjuvant Lynparza for BRCA-Mutant, High-Risk Early Breast Cancer Aug 25, 2022 AstraZeneca's Tagrisso, Lynparza Net Adjuvant Approvals in Japan Aug 12, 2022 In Brief This Week: AstraZeneca, Merck, Stemline Therapeutics, Caris Life Sciences, Artios Pharma Aug 4, 2022 Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early Breast Cancer Jul 29, 2022 AstraZeneca Q2 Oncology Sales Grow 14 Percent as Firm Awaits Key Precision Drug Regulatory Decisions Premium Jul 28, 2022 Merck's Keytruda Q2 Sales Grow 26 Percent; Firm Considers Future Impact of Medicare Price Setting Premium Jul 27, 2022 Celularity Begins Trial of NK Cell Therapy, Herceptin, Keytruda for HER2-Positive Gastric Cancer Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
